PFE
NYSE · Pharmaceuticals
Pfizer Inc.
$25.98
+0.17 (+0.64%)
PFE News30 articles
Pfizer Stock Rises as Core Drug Growth Offsets COVID Decline
Pfizer (PFE) shares rose 0.9% after Q2 results beat estimates, with non-COVID drug growth offsetting a steep decline in COVID product sales.
Pfizer Stock Rises as Non-COVID Drugs Offset Pandemic Revenue Slump
Pfizer's Q2 beat estimates as four growth brands offset COVID revenue declines. Shares rose 1.48% premarket.
Pfizer Beats Q2 Forecasts, Raises 2026 Sales Outlook
Pfizer's Q2 results beat expectations, driven by strong performance of key drugs, leading to a modest increase in its 2026 revenue forecast.
Bristol Myers Squibb at Crossroads as AstraZeneca Merger Talks Surface
Bristol Myers Squibb shares rose 5.2% last week after strong Q2 earnings, but a reported $400B merger approach from AstraZeneca puts the stock in focus Monday.
Pfizer Stock Climbs Ahead of Q2 Earnings on Strong Eliquis Sales Signal
Pfizer shares gained 2% this week ahead of Q2 earnings, bolstered by partner Bristol Myers' strong Eliquis sales and raised 2026 outlook.
Alnylam Shares Tumble 28% After Slashing Amvuttra Revenue Forecast
Shares of Alnylam Pharmaceuticals fell 28% after the firm lowered its Amvuttra revenue outlook, erasing $10.9 billion in equity value.
Pfizer Stock Edges Up Ahead of Q2 Report; Dividend Sustainability in Focus
Pfizer (PFE) shares edged higher ahead of its Q2 earnings report, as investors scrutinize whether the company's 7% dividend is sustainable amid cash flow pressures.
OPKO Stock Jumps 8% After Q2 Beat, Nicoya Deal Lifts Outlook
OPKO Health shares jumped 8% after hours as Q2 revenue beat by $32.35 million, largely from Nicoya preferred shares. The company also raised its 2026 revenue outlook.
Pfizer Stock Dips 1.9% but Dividend Adjusts Decline
Pfizer ended Friday at $24.54, down 1.9% unadjusted, but dividend-adjusted returns fell just 0.16%. The FDA's priority review for Talzenna offers a key catalyst for Q4.
TrumpRx Expansion to 800+ Drugs Heightens Tariff Risk for Generic Makers
Generic drug stocks fell after Trump announced tariffs up to 200% on imports by 2029, as TrumpRx expands to over 800 medications with 79 brand deals.
Pfizer Gains 3.6% as Dividend Yield Attracts Income Investors
Pfizer (PFE) shares climbed 3.6% as its 6.9% dividend yield attracted income-focused investors, despite unchanged analyst estimates and a slight earnings forecast cut.
TrumpRx Program Shows Limited Big Pharma Impact
TrumpRx's 79 presidential deals cover just 10% of branded drugs from 17 pharma firms, far below the touted 800. Major drugs like Ibrance and Biktarvy are excluded, limiting investor risk.
Pfizer Stock Rises as Sanofi Files Patent Suit Over COVID Vaccine Revenue
Pfizer shares gained 2.35% as Sanofi's patent lawsuit over Comirnaty targets past revenue rather than current sales, with modest financial risk relative to cash reserves.
Pfizer's 7% Dividend Yield Attracts Income Seekers Amid Market Turmoil
Pfizer (PFE) added 1.28% in post-market trading Monday, outperforming the broader market as investors rotated into defensive stocks amid geopolitical tensions and a tech selloff.
Pfizer Gains FDA Nod for Padcev Combo, Yet Stock Remains Flat
Pfizer's Padcev/Keytruda combo gets FDA approval for bladder cancer, but the stock dipped 0.33%. Wall Street remains cautious about revenue impact.
Moderna Plunges 11% as EU Vaccine Deal Lacks Minimum Purchase Guarantee
Moderna stock dropped 11.3% after the EU's RSV vaccine deal lacked a minimum purchase commitment, adding to investor worries about sales and cash burn.
Ionis Plunges 23% After Wainua Misses Key Goal in Heart Disease Trial
Ionis stock tumbled 23% after Wainua missed its primary endpoint in a major heart disease trial, erasing $3.2 billion in market value. The setback shifts attention to the company's TRYNGOLZA launch.
Pfizer Stock Rebounds After HSBC Downgrade, Dividend Yield Nears 7%
Pfizer shares recover some losses after HSBC downgrades the stock to Hold, slashing its price target by $4 to $28, as the dividend yield remains near 7%.
Pfizer's Dividend Sustainability in Focus After HSBC Downgrade
Pfizer shares slid after HSBC downgraded the stock, turning investor attention to the sustainability of its 7.3% dividend yield amid a payout ratio near 60% of adjusted EPS guidance.
Pfizer's 7% Yield Beckons as Stock Lingers Near $24
Pfizer (PFE) trades near $24 with a 7.1% yield after a flat week. The company's Q1 dividends rivaled R&D spending, underscoring a focus on shareholder returns.
Pfizer's 7% Yield Attracts Income Seekers as Pharma Sector Stalls
Pfizer shares edged up 1.84% to $24.32, offering a 7.07% yield, but the stock has declined 14.12% over the past three months amid a sluggish pharmaceutical sector.
Moderna Surges 10% as Flu Vaccine Hopes Add $2.9B to Market Cap
Moderna shares surged over 10% in after-hours trading, adding roughly $2.9 billion in market value as investor enthusiasm for its flu vaccine pipeline continues to build.
AbbVie Surges $17.8 Billion in Market Cap, Surpassing Apogee Deal Value
AbbVie shares soared 3.99% to $261.07, adding $17.8B in market value—more than the $10.9B Apogee deal. The stock now trades above analyst targets, setting up a key Q2 earnings report.
Pfizer Gains as 7% Yield Attracts, China Trial Scrutiny Looms
Pfizer (PFE) shares climbed 2.1% on Thursday, supported by a high dividend yield, but a U.S. House committee probe into its China trial data adds uncertainty.
Nike shares climb on tariff relief, masking flat North America profit
Nike shares gained 4.9% on Wednesday after Q4 earnings got a $0.52 per share lift from tariff recoveries, but adjusted North America EBIT was nearly flat.
Pfizer's Dividend Yield Surges Past 7% as GLP-1 News Weighs on Stock
Pfizer's stock dropped 0.9% to $24.14, boosting its implied dividend yield above 7% after news of a GLP-1 access route in China.
Pfizer Gains on China GLP-1 News, but Dividend Focus Limits Upside
Pfizer shares edged up 0.4% after its GLP-1 drug cleared a China insurance review, but the stock trails the S&P 500 as investors weigh dividend yield against growth prospects.
Lilly Surges on EU Leukemia Drug Approval; Pre-Market Nears Analyst Target
Eli Lilly shares jumped 7.13% to a record $1,208.12 Friday, adding $75.7B in market cap after EU regulators recommended Jaypirca for chronic lymphocytic leukemia.
Pfizer Rebounds After Cancer Setback, Dividend Sustainability in Spotlight
Pfizer shares bounced 2.6% Friday after six straight declines, as investors weighed a dividend payout against a failed lung cancer study, an FDA win for Ibrance, and a pending CFO change.
Pfizer's 7% Yield Draws Income Investors Amid Mixed Drug News
Pfizer's yield surpasses 7% as shares decline, FDA clears Ibrance for expanded use, but a lung cancer drug fails late-stage trial, highlighting income appeal versus uneven growth.